FDA approves AbbVie's Juvmo (tavapadon) for Parkinson's, a D1/D5 agonist from its $8.7B Cerevel buy with fewer side effects ...
Endpoints News announces the winners of the 2026 Endpoints 11 awards: The best and most exiting biotech startups of the year.
Clive Meanwell and John Maraganore's Corsera Health is developing a once-yearly siRNA shot to prevent heart disease in ...
SonoThera is using ultrasound and microbubbles to push full-length dystrophin into muscle, with a $125M Series B and a 2027 ...
Nektar wins $90M from Lilly in a licensing fight over rezpeg — far short of the roughly $1B it sought. Lilly plans to appeal.
Endpoints 11 winner Stipple Bio is aiming to be part of the future generation of therapies used for deadly pancreatic cancer.
Brian Armstrong, Blake Byers Headquarters South San Francisco, CA Total raised $682M Key investors Kleiner Perkins, Founders ...
Vivodyne, backed by about $80M, grows vascularized human tissues to screen drugs as the FDA and NIH push alternatives to animal testing.
Weihao Xu built Kali Therapeutics with $18M, no lab and Chinese vendors — then sold its lead T cell engager to Sanofi for ...
FDA approved Mirum's Atebrioz (zilurgisertib) for FOP, a rare disease turning muscle to bone, joining Ipsen's Sohonos & ...
Doudna-co-founded Azalea Therapeutics aims to enter the clinic next year with a CRISPR-based in vivo CAR-T therapy for blood ...
Alnylam alumni-led City Therapeutics files for a Nasdaq IPO under CTY, with $172M in cash and a Phase 1 factor XI siRNA.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results